What is NAD+? A research overview

NAD+ is one of the most talked-about molecules in longevity and metabolism research — and, like most such molecules, one whose popular description tends to run well ahead of the evidence. The purpose of this overview is to summarise, accurately and without embellishment, what the published literature says NAD+ is and does at the cellular level, and what that literature does not establish about outcomes in people. Everything below is framed as "the research describes" or "studies report." Nothing here is a claim of benefit or a recommendation of any kind.

What NAD+ is

NAD+ stands for nicotinamide adenine dinucleotide. It is a coenzyme — a small helper molecule — found in every living cell, built from two nucleotides joined through their phosphate groups. It exists in two interconverting forms: an oxidised form (NAD+) and a reduced form (NADH). That NAD+/NADH pair is one of the cell's central redox couples: it carries electrons between reactions, which is the chemical basis for how cells extract energy from nutrients. NAD+ is not a peptide — it is a dinucleotide coenzyme, and in a research setting it is handled as a laboratory reagent.

The role it plays in the cell

Published reviews describe NAD+ as sitting at the intersection of two broad functions. First, its redox role: as the NAD+/NADH couple it shuttles electrons through the reactions of central metabolism — glycolysis, the TCA cycle, oxidative phosphorylation — making it fundamental to how cells produce ATP. Second, a signalling and consumption role: several families of enzymes consume NAD+ as a substrate rather than merely borrowing its electrons. The most discussed are the sirtuins (a family of protein deacylases) and the PARPs (poly-ADP-ribose polymerases, involved in DNA-damage responses), along with CD38 and related enzymes. Because these enzymes break NAD+ down as they work, the cell must continually resynthesise it — and that is the link between "NAD+ levels" and the ageing-research interest described below (Covarrubias et al., 2021).

NAD+ metabolism: how the cell makes and spends it

The reason NAD+ metabolism became a research field of its own is this balance between synthesis and consumption. Reviews describe multiple biosynthetic routes — a de novo pathway from tryptophan, and salvage pathways that recycle precursors such as nicotinamide, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) back into NAD+ (Katsyuba et al., 2020). Much of the experimental literature on "raising NAD+" concerns these precursors: whether supplying NR or NMN increases NAD+ in cells and tissues in model systems, and what happens downstream. This overview describes that these pathways are studied; it does not assert an outcome.

Research areas described in published reviews

Published review articles group the NAD+ literature into a few broad, overlapping areas. What follows summarises what those reviews describe as having been studied — largely in cell and animal models — not established effects in people.

Ageing biology

A 2015 review in Science set out the case for NAD+ as a node in ageing biology, linking declining NAD+ availability in model systems to mitochondrial and metabolic changes (Verdin, 2015). That framing — NAD+ decline with age in animal models, and what restoring it does in those models — is the spine of the field.

Metabolism and mitochondrial function

Reviews collate preclinical work on NAD+ and energy metabolism, describing studies in which NAD+-boosting molecules were investigated in metabolic and mitochondrial models (Rajman, Chwalek & Sinclair, 2018). As throughout, these are laboratory and animal studies.

DNA repair and cellular stress responses

Because PARP enzymes consume NAD+ during DNA-damage responses, a further cluster of the literature examines NAD+ in the context of genomic stress and repair in cell models (Covarrubias et al., 2021).

Study stage and the evidence gap

It is worth stating the evidence picture directly, because this is the field where it is most often blurred. The NAD+ literature is large, well-funded, and genuinely foundational at the level of basic biochemistry — the redox role of NAD+/NADH is textbook, settled science. The translational layer — the idea that raising NAD+ with precursors produces meaningful health outcomes in humans — is much earlier. Human trials of precursors such as NR and NMN have largely focused on safety and on whether blood or tissue NAD+ rises, with outcome data limited and mixed (Rajman, Chwalek & Sinclair, 2018; Katsyuba et al., 2020). In short: rock-solid basic biochemistry, an active and serious preclinical literature, and a genuine gap where large, independent human outcome trials would be. That gap is precisely why NAD+ and its precursors are supplied as research reagents and not as medicines.

Stability and format notes

As a laboratory reagent, NAD+ behaves like other hygroscopic biochemical cofactors and is considerably more delicate in solution than as a dry solid:

• Format: typically supplied as a lyophilised or crystalline powder, reconstituted into a stock solution with an appropriate diluent when a study requires it.
• Storage: the dry solid is far more stable than the solution — keep cold, dry and dark per general reagent practice.
• In solution: NAD+ can degrade, so aliquoting and freezing to avoid repeated freeze–thaw is standard, along with the same cold, dark, gentle-handling habits that apply to sensitive cofactors generally.

The site's reconstitution & storage guide covers general laboratory handling, and the reconstitution calculator handles the concentration arithmetic.

Regulatory status

NAD+ is not an authorised medicine. It has no marketing authorisation in the European Union or Ireland as a therapeutic product, and neither NAD+ nor its precursors are approved treatments for any condition in a way that would place them in the licensed-medicine category. NAD+ is studied as a research compound; in some jurisdictions certain precursors are sold as dietary ingredients under separate food-supplement regimes, which is a distinct legal category from medicines and should not be read across. Because NAD+ as supplied here corresponds to no authorised medicine, it is provided strictly as a laboratory reagent, described factually and without human-use claims — the same posture set out in the site's Ireland legality & customs explainer. Anyone weighing the regulatory position for a specific purpose should consult the relevant competent authority or a qualified professional.

How to read this literature

Three habits keep interpretation honest:

• Separate the biochemistry from the claims. NAD+'s redox role is settled textbook science; "boosting NAD+ improves X in humans" is a separate, much earlier and largely unproven proposition. Do not let the first lend borrowed certainty to the second — this is the single most common error in writing about NAD+.
• Distinguish model from meaning. "NAD+ rose in a mouse tissue" describes an experiment, not a promise about outcomes in people.
• Read primary sources. The reviews cited below are entry points into the underlying studies; the abstracts and full texts are the authoritative record, not third-hand summaries.

Frequently asked

Sources

Peer-reviewed review articles indexed on PubMed. Every citation below was verified against PubMed on 22 July 2026.